Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Vivani Medical and keeping the price target at $4.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Naz Rahman has given his Buy rating due to a combination of factors that highlight Vivani Medical’s strategic focus and promising developments. The company is prioritizing the development of its NPM-139 semaglutide implant, which has shown encouraging preclinical results, including a significant weight loss in animal studies. This implant aims to address the issue of patient non-compliance with existing weekly injection treatments by offering a longer-lasting solution.
Furthermore, the financial position of Vivani Medical appears stable, with recent funding expected to support operations and the next phase of clinical trials. The familiarity of semaglutide, already known for its use in Ozempic/Wegovy, provides a solid foundation for future regulatory filings and market acceptance. Rahman anticipates a substantial market opportunity for Vivani’s innovative approach to obesity treatment, reinforcing his Buy recommendation.
In another report released on August 5, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VANI in relation to earlier this year.